Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
  • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
  • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
  • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
  • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/60—Salicylic acid; Derivatives thereof
  • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
  • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

• the present invention relates to a pharmaceutical composition in the form of a tablet having three or more layers which includes aspirin in one layer and pravastatin in a second layer, which layers are separated from each other by at least one middle barrier layer, in a manner to minimize interaction of aspirin with the statin, for use in lowering cholesterol and reducing risk of a myocardial infarction, and to a method for lowering cholesterol and reducing risk of a myocardial infarction employing such composition.
• statins for lowering cholesterol and preventing or treating atherosclerosis and cardiovascular disease and cerebrovascular disease are well documented. In fact, it is not uncommon that patients having elevated cholesterol levels who are at high risk for a myocardial infarction take both a statin and aspirin. However, use of both a statin and aspirin may require special care to insure that drug interaction, including physical and chemical incompatibility, and side effects, are kept to a minimum while achieving maximum benefit from these drugs.
• statin is an acid
• statins such as pravastatin, atorvastatin and cerivastatin
• statins alkali salts
• pravastatin is an acid labile compound.
• pravastatin and aspirin are combined, the aspirin could cause pravastatin degradation which could result in reduced bioavailability of pravastatin.
• Aspirin is known for causing gastrointestinal irritation and possibly bleeding when used for long-term therapy. It is therefore desirable in long-term aspirin therapy that the aspirin be provided in a form which minimizes side effects, for example a buffered aspirin formulation.
• statin-aspirin formulation which provides for maximum cholesterol lowering and reduction of risk of a myocardial infarction without the undesirable side effects and drug interaction normally associated with use of such combination.
• U.S. Patent No. 6,235,311 to Ullah et al. discloses a bilayered tablet which includes aspirin in a first layer and a statin in a second layer, which tablet is formulated to minimize interaction between aspirin and the statin.
• the layer containing the statin includes one or more buffering agents to inhibit undesirable statin/aspirin interaction.
• WO94/06416 discloses a three-layered tablet which includes an outer immediate release layer, an outer slow release layer, and a middle barrier layer, which may contain a buffer, which separates the immediate release layer from the slow release layer.
• drugs which may be present in the tablets are non-steroidal anti-inflammatory agents.
• U.S. Patent No. 4,590,183 to Bailey discloses a multi-layered tablet which contains aspirin and sodium thiosulfate which may be separated from each other by an inert barrier.
• a pharmaceutical composition which is preferably in the form of a tablet containing pravastatin and aspirin formulated to reduce and/or inhibit pravastatin: aspirin interaction.
• the tablet of the invention is preferably in the form of a sandwich structure which includes one layer containing aspirin, another layer containing pravastatin, and one or more intermediate or middle barrier layers or other functional layers which separate the aspirin and pravastatin layers and minimizes interaction between the ingredients in these layers; one or more of these layers may optionally contain active ingredients such as a buffering agent which will help reduce the gastric irritation aspirin could cause.
• the tablet may include an aspirin layer and a pravastatin layer separated by an intermediate or middle barrier layer with an additional layer or layers applied to the outer face of the pravastatin layer, the aspirin layer or both.
• additional layers can be for aesthetic purposes, to disguise the taste of the drug substances, and/or to provide for delivery of additional active materials, such as buffers or other ingredients such as niacin, which are often co-administered with statins.
• the tablet of the invention provides for maximum patient benefits including maximum cholesterol lowering and reduced risk of a myocardial infarction with minimal physical and chemical incompatibility (including minimal pravastatin: aspirin interaction), and reduced side effects normally associated with use of such drugs.
• a method for lowering serum cholesterol, preventing or inhibiting or treating atherosclerosis, and/or reducing risk of or treating a cardiovascular event or disease including coronary artery disease and cerebrovascular disease, wherein a pharmaceutical composition containing a combination of pravastatin and aspirin in a single dosage form, as described above, in a manner so as to minimize interaction of the pravastatin and aspirin, is administered to a patient in need of treatment.
• a pharmaceutical composition is provided as a trilayered sandwich structure wherein the pravastatin and aspirin are formulated together in a single tablet.
• the tablet of the invention is preferably in the form of a trilayered tablet which includes a first layer, a second layer in the form of a middle barrier layer and a third layer.
• Aspirin in the form of granules or crystals of a defined size will be present in the first layer together with optional excipients as described hereinafter, while the pravastatin will be present in the third layer.
• the middle barrier layer optionally, but preferably, includes one or more buffering agents (as necessary to reduce, inhibit or prevent undesirable statin/aspirin interaction) and optionally one or more excipients as described hereinafter.
• the trilayered tablet of the invention may include an outer protective coating or finishing layer covering the first layer and/or third layer as described hereinafter.
• a pharmaceutical composition which is in the form of a trilayered tablet as described above which includes in one outer layer aspirin granules having an enteric coating to provide maximum efficacy while minimizing side effects resulting from prolonged aspirin therapy.
• Another embodiment of the pharmaceutical composition of the invention includes granules of enteric coated aspirin in the first layer and enteric coated pravastatin in the third layer.
• the tablets containing the enteric coated granules of aspirin and statin may also include an outer protective coating or finishing layer.
• the pharmaceutical composition of the invention which includes a combination of pravastatin and aspirin is effective in preventing, reducing and/or treating elevated cholesterol levels (such as in hypercholesterolemia), atherosclerosis, cardiovascular events and disease including coronary events and cerebrovascular events, and coronary artery disease and/or cerebrovascular disease.
• cardiac event(s) and cardiac disease refer to coronary and/or cerebrovascular event(s) and disease including primary myocardial infarction, secondary myocardial infarction, myocardial ischemia, angina pectoris (including unstable angina), congestive heart failure, sudden cardiac death, cerebral infarction, cerebral thrombosis, cerebral ischemia, transient ischemic attack and the like.
• CAD coronary artery disease
• cancer cardiovascular disease
• atherosclerosis of the intracranial and/or extracranial arteries, cerebral infarction, cerebral thrombosis, cerebral ischemia, stroke, and/or transient ischemic attacks.
• pravastatin refers to pravastatin, pravastatin sodium, other pravastatin salts, and all forms of pravastatin including the dihydroxy acid form and the lactone form.
• Aspirin will preferably be employed in the form of acetylsalicylic acid also referred to as salicylic acid acetate, or its salts, esters or complexes.
• the pharmaceutical composition of the invention in the form of a tablet will include aspirin in amounts from about 10 to about 800 mg, preferably from about 25 to about 650 mg, most preferably from about 50 to about 325mg.
• the aspirin for use in forming the pharmaceutical composition of the invention will preferably be in the form of granules having an average particle size within the range from about 10 microns to about 2 mm, more preferably from about 50 microns to about 1.0 mm.
• the pharmaceutical composition of the invention will contain pravastatin in an amount as normally employed as exemplified in the 56 th Edition of the Physician's Desk Reference (PDR) (2002).
• pravastatin may be employed in amounts within the range from about 0.1 mg to 2000 mg per day in single or divided doses, and preferably from about 0.2 to about 200 mg per day, and most preferably, a daily dosage of 10 to 160 mg may be employed in single or divided doses.
• the first layer containing aspirin will optionally, but preferably, include bulking agents such as lactose, microcrystalline cellulose, wood cellulose, corn starch, modified corn starch, calcium phosphate, sugar, dextrose, mannitol, sorbitol or mixtures of two or more thereof.
• the bulking agent will be present in an amount from about 1 to about 90%, preferably from about 5 to about 85% by weight of the first layer containing aspirin.
• the first layer may also optionally include a tabletting lubricant, such as zinc stearate, magnesium stearate, calcium stearate, talc, carnauba wax, stearic acid, palmitic acid or hydrogenated vegetable oils and fats, in an amount within the range from about 0.1 to about 4%, and preferably 0.2 to about 2% by weight of the first layer.
• the aspirin layer may also optionally include a disintegrant such as corn starch, potato starch, pre-gelatinised starch, crospovidone, croscarmellose sodium or sodium starch glycollate in an amount within the range from about 0.5 to about 20% by weight of the layer, and preferably from about 1 to about 10% by weight of the layer.
• the third layer of the trilayered tablet containing pravastatin cholesterol lowering agent will optionally include a bulking agent such as lactose, microcrystalline cellulose, modified corn starch, calcium phosphate or other bulking agent as set out above for the first layer, in an amount within the range from about 1 to about 90%, preferably from about 5 to about 85% by weight of the third layer.
• a bulking agent such as lactose, microcrystalline cellulose, modified corn starch, calcium phosphate or other bulking agent as set out above for the first layer, in an amount within the range from about 1 to about 90%, preferably from about 5 to about 85% by weight of the third layer.
• the third layer may optionally include a binder such as corn starch, pregelatinized starch, polyvinyl pyrrolidone (PVP), hydroxypropylmethyl cellulose (HPMC), ethyl cellulose, cellulose acetate and the like, in an amount within the range from about 0.5 to about 20%, preferably from about 1 to about 10% by weight of the third layer, a disintegrating agent, such as croscarmellose sodium, crospovidone, pre- gelatinised starch, corn starch or sodium starch glycollate in an amount within the range from about 0.5 to about 20% by weight, preferably from about 1 to about 15% by weight of the third layer, and a tabletting lubricant such as magnesium stearate, zinc stearate, or other lubricant as set out above with respect to the first layer in an amount from about 0.1 to about 4%, preferably from about 0.2 to about 2% by weight of the third layer.
• a binder such as corn starch, pregelatinized starch,
• the third layer containing pravastatin may also optionally include one or more buffering agents which include conventional acid buffers such as calcium carbonate, magnesium oxide, magnesium carbonate, magnesium hydroxide, aluminum hydroxide, dihydroxyaluminum sodium carbonate, aluminum magnesium hydroxide sulfate or aluminum hydroxide magnesium carbonate co-dried gel, or any of the acid buffers set out for use in the middle barrier layer, or mixtures of one or more thereof, in amounts as needed to insure that the aspirin will be sufficiently buffered to inhibit GI side effects.
• buffering agent within the range from about 10 to about 800 mg, preferably from about 70 to about 300 mg will be employed depending upon the amount of aspirin present in the first layer.
• the middle or barrier layer will optionally include a bulking agent such as any of the bulking agents set out above for use in the first (aspirin) layer or third
• (pravastatin) layer such as microcrystalline cellulose, corn starch, lactose, and the like, in an amount within the range from about 0 to about 90%, preferably from about 5 to about 85% based on the weight of the middle barrier layer; a disintegrating agent such as any of the disintegrating agents set out above with respect to the third (pravastatin) layer in an amount with the range from about 0.5 to about 20%, preferably from about 1 to about 15% by weight of the middle barrier layer; a tabletting lubricant, such as any of the tabletting lubricants set out above with respect to the first layer and the third layer, in an amount within the range from about 0.1 to about 4%, preferably from about 0.2 to about 2% by weight of the middle barrier layer.
• a disintegrating agent such as any of the disintegrating agents set out above with respect to the third (pravastatin) layer in an amount with the range from about 0.5 to about 20%, preferably from about 1 to about 15% by weight of the middle barrier layer
• the middle barrier layer may optionally, but preferably, include a buffering agent in an amount sufficient to reduce gastric irritation that can be caused by aspirin and insure that the aspirin will be sufficiently buffered to minimize interaction between the aspirin and pravastatin.
• buffering agent within the range from about 10 to about 800 mg, preferably from about 70 to about 300 mg, depending upon the amount of aspirin present in the first layer.
• buffering agent suitable for use in the middle barrier layer examples include calcium carbonate, magnesium oxide, magnesium carbonate, magnesium hydroxide, calcium hydroxide, sodium phosphate, aluminum hydroxide, dihydroxyaluminum sodium carbonate, sodium carbonate, sodium bicarbonate, aluminum magnesium hydroxide sulfate or aluminum hydroxide, magnesium carbonate co-dried gel, sodium acetate, sodium citrate, sodium tartrate, sodium fumarate, sodium malate, sodium succinate, aluminum oxide, or mixtures of two or more thereof.
• Preferred trilayered tablet formulations of the invention are set out below.
• Disintegrating Agents 0.5 to 15 2 to 60
• trilayered tablet formulations of the invention are set out below. I. One to three trilayered tablet(s) containing pravastatin-aspirin where the middle barrier layer includes one or more buffering agents.
• Microcrystalline Cellulose O to 50 0 to 250
• Microcrystalline Cellulose O to 25 0 to 250
• the first layer containing aspirin, the third layer containing pravastatin and the middle barrier layer may each be prepared by conventional wet granulation, dry granulation (compaction) or dry blending techniques.
• the first, middle and third layers may then be compressed and combined to form a trilayered tablet employing conventional trilayer tabletting equipment.
• Other conventional ingredients which may optionally be present in any of the three layers include preservatives, stabilizers, anti-adherents or silica flow conditioners or glidants, such as Syloid brand silicon dioxide as well as antioxidants such as Vitamin E, Vitamin C, and folic acid, Vitamin B 6 and Vitamin B ⁇ 2 .
• the trilayer tablet of the invention may also include an outer protective coating layer which may include up to about 15% by weight of the trilayer tablet.
• the outer protective coating layer which is applied over the trilayered tablet may comprise any conventional coating formulations and will include one or more film-formers, such as a hydrophihc polymer like hydroxypropylmethyl cellulose (HPMC) and a hydrophobic polymer like ethyl cellulose, cellulose acetate, polyvinyl alcohol-maleic anhydride copolymers, acrylic copolymers, ⁇ -pinene polymers, glyceryl esters of wood resins and the like, and one or more plasticizers, such as polyethylene glycol, triethyl citrate, diethyl phthalate, propylene glycol, glycerin, butyl phthalate, castor oil and the like.
• film-formers such as a hydrophihc polymer like hydroxypropylmethyl cellulose (HPMC) and a hydrophobic polymer like ethy
• the film formers are applied from a solvent system containing one or more solvents including water, alcohols like methyl alcohol, ethyl alcohol or isopropyl alcohol, ketones like acetone, or ethylmethyl ketone, chlorinated hydrocarbons like methylene chloride, dichloroethane, and 1,1,1-trichloroethane.
• solvents including water, alcohols like methyl alcohol, ethyl alcohol or isopropyl alcohol, ketones like acetone, or ethylmethyl ketone, chlorinated hydrocarbons like methylene chloride, dichloroethane, and 1,1,1-trichloroethane.
• composition of the invention is formed of trilayered tablets containing enteric coated aspirin granules in the first layer.
• the aspirin granules can be coated with conventional enteric polymers coatings in aqueous or non-aqueous systems.
• enteric polymers for example, Eudragit L-30D-55 (acrylic acid copolymers-Rohm Pharma) (5 to 25% solids) containing 10 to 15% of diethylphthlate (w/w) as plasticizer can be used in an aqueous system.
• enteric polymer coating systems may be employed such as Eudragit R and S series resins, (acrylic acid copolymers-Rohm Pharma), cellulose acetate phthalate, cellulose acetate maleate, cellulose acetate succinate, hydroxypropylmethyl cellulose phthalate, hydroxypropylmethylcellulose acetate succinate, and the like, and a suitable plasticizer such as triethyl citrate, diethyl phthalate, tributyl citrate, triacetin, dibutyl phthalate, dibutyl sebicate, Myvacet 940, and other commonly used plasticizers as may be suitable for particular enteric polymers can be used. It will be appreciated that any polymer with suitable plasticizer can be used in aqueous or non-aqueous system to form an enteric coating on the aspirin granule or particle.
• suitable plasticizer such as triethyl citrate, diethyl phthalate, tributyl citrate, triacetin, dibuty
• the enteric coated aspirin granules described above may be further coated with an outer protective finishing coat or layer as described hereinbefore.
• the double coated aspirin granules can be tableted as described above.
• aspirin is enteric coated as described above and the pravastatin can optionally be enteric coated.
• Pravastatin can be coated in the form of pure drug or after spheronization or agglomeration. The particles for coating do not need to be perfectly spherical. These could be rods or irregular particles.
• the pharmaceutical composition of the invention containing the combination of the pravastatin and aspirin may be administered to mammalian species, such as monkeys, dogs, cats, rats, humans, etc., and, as described hereinbefore, may be incorporated in a trilayered tablet.
• the above dosage forms will also include the necessary carrier material, excipient, lubricant, buffer, antibacterial, bulking agent (such as mannitol), antioxidants such as Vitamin C and Vitamin E, as well as Vitamin B , Vitamin Bj 2 , folic acid, sodium bisulfite, and the like.
• the dose administered must be adjusted according to age, weight and condition of the patient, as well as the route of administration, dosage form and regimen and the desired result.
• compositions described above may be administered in the dosage forms as described above in single or divided doses of one to four times daily. It may be advisable to start a patient on a low dose combination and work up gradually to a high dose combination. Tablets of various sizes can be prepared, e.g., up to about 1500 mg in total weight, containing the active substances in the ranges described above. These tablets can, of course, be scored to provide for fractional doses in some cases.
• Some of the active substances described above form commonly known, pharmaceutically acceptable salts such as alkali metal and other common basic salts or acid addition salts, etc. References to the base substances are therefore intended to include those common salts known to be substantially equivalent to the parent compound.
• formulations as described above will be administered for a prolonged period, that is, for as long as the potential for cardiovascular events and disease including coronary artery disease and/or cerebrovascular disease remains or the symptoms continue.
• Sustained release forms of such formulations which may provide such amounts daily, biweekly, weekly, monthly and the like may also be employed.
• a dosing period of at least 10 days are required to achieve minimal benefit.
• Formulations suitable for oral administration are prepared as described below.
• a trilayered tablet containing 81 mg aspirin in a first outer layer and 40 mg pravastatin sodium in a second outer layer with a buffered intermediate layer may be prepared as follows.
• a wet granulation process is used to prepare pravastatin granules, dissolving the pravastatin sodium and the povidone in purified water and using this solution to granulate the mixture of the other first layer ingredients except for the zinc stearate.
• the granules are dried, sieved and lubricated by mixing with the zinc stearate.
• the second, intermediate layer components are mixed together dry in a suitable tumble blender.
• the aspirin layer components except for zinc stearate, are combined by mixing in a suitable tumble blender.
• the zinc stearate is then added to this mixture and mixing continued to lubricate the blend.
• the three layer tablets are prepared by having the granules of powder mixes for each layer in separate hoppers on a tablet press designed for the manufacture of layered tablets. Operating the tablet press results in triple layers tablets containing
• Example 1 The purified water in the first layer in Example 1 (as well as in Examples 2 to 6 and 8 to 10) is used for wet granulation and removed during drying.
• the tribuffer alkaline granules used in the Example 1 formulation and in Examples 2 to 9 has the following composition: calcium carbonate 52.63%w/w, magnesium oxide heavy 21.05% w/w, magnesium carbonate 13.16% w/w, monobasic sodium phosphate 1.32 %w/w, cornstarch 10.52 % w/w, citric acid 1.32 % w/w.
• the aspirin 10% starch granules used in the Example 1 formulation and in Examples 2 to 10 is obtained from Rhodia, Cranbury NJ, USA. 81 mg of aspirin and 40 mg of pravastatin sodium possessing an intermediate layer containing alkaline earth buffers.
• EXAMPLE 2 A trilayered tablet containing 325 mg aspirin in a first outer layer and 40 mg pravastatin sodium in a second outer layer and an intermediate layer containing buffering agents may be prepared as follows.
• a trilayered tablet containing 81 mg aspirin in a first outer layer and 80 mg pravastatin sodium in a second outer layer with a buffered intermediate layer may be prepared as follows.
• a wet granulation process is used to prepare pravastatin granules, dissolving the pravastatin sodium and the povidone in purified water and using this solution to granulate the mixture of the other first layer ingredients except for the zinc stearate.
• the granules are dried, sieved and lubricated by mixing with the zinc stearate.
• the second, intermediate layer components are mixed together dry in a suitable tumble blender.
• the aspirin layer components except for zinc stearate, are combined by mixing in a suitable tumble blender.
• the zinc stearate is then added to this mixture and mixing continued to lubricate the blend.
• the three layer tablets are prepared by having the granules of powder mixes for each layer in separate hoppers on a tablet press designed for the manufacture of layered tablets. Operating the tablet press results in triple layers tablets containing 81 mg of aspirin and 80 mg of pravastatin sodium possessing an intermediate layer containing alkaline earth buffers.
• EXAMPLE 4 A trilayered tablet containing 325 mg aspirin in a first outer layer and 80 mg pravastatin sodium in a second outer layer and an intermediate layer containing buffering agents may be prepared as follows.
• the components of the three layers are processed as per Example 1 and the granules transferred to a rotary tablet press designed for making layered tablets which is operated to yield tablets containing 325 mg of aspirin and 80 mg of pravastatin sodium with an intermediate layer containing alkaline earth buffers.
• EXAMPLE 5 A trilayered tablet containing 81 mg aspirin in a first outer layer and 40 mg pravastatin sodium in a second outer layer and an intermediate layer containing alkaline earth buffering agents may be prepared as follows.
• the components of the three layers are processed as per example 1 and the granules transferred to a rotary tablet press designed for making layered tablets which is operated to yield tablets containing 81 mg of aspirin and 80 mg of pravastatin sodium with an intermediate layer containing alkaline earth buffers.
• EXAMPLE 6 A trilayered tablet containing 81 mg aspirin in a first outer layer and 40 mg pravastatin sodium in a second outer layer and an intermediate layer containing alkaline earth buffering agents may be prepared as follows.
• a wet granulation process is used to prepare pravastatin granules; the pravastatin sodium and the povidone are dissolved in purified water and this solution is used to granulate the mixture of the other first layer ingredients except for the zinc stearate.
• the granules are dried, sieved and lubricated by mixing with the zinc stearate.
• the second, intermediate layer components are mixed together dry in a suitable tumble blender.
• the aspirin layer components except for zinc stearate, are combined by mixing in a suitable tumble blender.
• the zinc stearate is then added to this mixture and mixing continued to lubricate the blend.
• the triple layer tablets are prepared by having the granules of powder mixes for each layer in separate hoppers on a tablet press designed for the manufacture of layered tablets. Operating the tablet press results in triple layers tablets containing 81 mg of aspirin and 40 mg of pravastatin sodium possessing an intermediate layer containing alkaline earth buffers.
• EXAMPLE 7 A trilayered tablet containing 81 mg aspirin in a first outer layer and 40 mg pravastatin sodium in a second outer layer and an intermediate layer containing alkaline earth buffering agents may be prepared as follows.
• a direct compression process is used to prepare the pravastatin layer by blending the pravastatin sodium and the other first layer ingredients except for the zinc stearate in a suitable mixer until uniform. This powder blend is then lubricated by further mixing with the zinc stearate.
• the second, intermediate layer components are mixed together dry in a suitable tumble blender.
• the aspirin layer components except for zinc stearate, are combined by mixing in a suitable tumble blender.
• the zinc stearate is then added to this mixture and mixing continued to lubricate the blend.
• the triple layer tablets are prepared by having the granules of powder mixes for each layer in separate hoppers on a tablet press designed for the manufacture of layered tablets. Operating the tablet press results in triple layered tablets containing 81 mg of aspirin and 40 mg of pravastatin sodium possessing an intermediate layer containing alkaline earth buffers.
• EXAMPLE 8 A trilayered tablet containing 81 mg aspirin in a first outer layer and 20 mg pravastatin sodium in a second outer layer (made by a wet granulation process) and an intermediate layer containing alkaline earth buffering agents may be prepared as follows.
• a wet granulation process is used to prepare pravastatin granules, dissolving the pravastatin sodium and the povidone in purified water and using this solution to granulate the mixture of the other first layer ingredients except for the zinc stearate.
• the granules are dried, sieved and lubricated by mixing with the zinc stearate.
• the second, intermediate layer components are mixed together dry in a suitable tumble blender.
• the aspirin layer components except for zinc stearate, are combined by mixing in a suitable tumble blender.
• the zinc stearate is then added to this mixture and mixing continued to lubricate the blend.
• the triple layer tablets are prepared by having the granules of powder mixes for each layer in separate hoppers on a tablet press designed for the manufacture of layered tablets. Operating the tablet press results in triple layers tablets containing 81 mg of aspirin and 20 mg of pravastatin sodium possessing an intermediate layer containing alkaline earth buffers
• EXAMPLE 9 A trilayered tablet containing 325 mg aspirin in a first outer layer and 20 mg pravastatin sodium in a second outer layer (made by a wet granulation process) and an intermediate layer containing alkaline earth buffering agents may be prepared as follows.
• a wet granulation process is used to prepare pravastatin granules, dissolving the pravastatin sodium and the povidone in purified water and using this solution to granulate the mixture of the other first layer ingredients except for the zinc stearate.
• the granules are dried, sieved and lubricated by mixing with the zinc stearate.
• the second, intermediate layer components are mixed together dry in a suitable tumble blender.
• the aspirin layer components except for zinc stearate, are combined by mixing in a suitable tumble blender.
• the zinc stearate is then added to this mixture and mixing continued to lubricate the blend.
• the triple layer tablets are prepared by having the granules of powder mixes for each layer in separate hoppers on a tablet press designed for the manufacture of triple layered tablets. Operating the tablet press results in triple layers tablets containing 81 mg of aspirin and 20 mg of pravastatin sodium possessing an intermediate layer containing alkaline earth buffers.
• a trilayered tablet containing 81 mg of aspirin in the first outer layer and 40mg pravastatin sodium in a second outer layer and a non-buffered intermediate layer may be prepared as follows:
• a wet granulation process is used to prepare pravastatin granules, dissolving the pravastatin sodium and the povidone in purified water and using this solution to granulate the mixture of the other first layer ingredients except for the zinc stearate.
• the granules are dried, sieved and lubricated by mixing with the zinc stearate.
• the second, intermediate layer components are mixed together dry in a suitable tumble blender.
• the aspirin layer components except for zinc stearate, are combined by mixing in a suitable tumble blender.
• the zinc stearate is then added to this mixture and mixing continued to lubricate the blend.
• the triple layer tablets are prepared by having the granules of powder mixes for each layer in separate hoppers on a tablet press designed for the manufacture of layered tablets. Operating the tablet press results in triple layers tablets containing 81 mg of aspirin and 40 mg of pravastatin sodium possessing an unbuffered intermediate layer.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Epidemiology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Emergency Medicine (AREA)
• Heart & Thoracic Surgery (AREA)
• Cardiology (AREA)
• Urology & Nephrology (AREA)
• Vascular Medicine (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (8)

Applications Claiming Priority (2)

Publications (2)

Family

ID=32505946

Family Applications (1)

Country Status (17)

Cited By (7)

Families Citing this family (19)

Family Cites Families (8)

• 2002
  • 2002-12-11 US US10/316,424 patent/US20040115265A1/en not_active Abandoned
• 2003
  • 2003-12-03 WO PCT/US2003/038774 patent/WO2004052289A2/en not_active Ceased
  • 2003-12-03 EP EP03812825A patent/EP1581194B1/en not_active Expired - Lifetime
  • 2003-12-03 AT AT03812825T patent/ATE401061T1/de active
  • 2003-12-03 PL PL377265A patent/PL206190B1/pl unknown
  • 2003-12-03 ES ES03812825T patent/ES2308040T3/es not_active Expired - Lifetime
  • 2003-12-03 AU AU2003297689A patent/AU2003297689A1/en not_active Abandoned
  • 2003-12-03 PT PT03812825T patent/PT1581194E/pt unknown
  • 2003-12-03 DE DE60322264T patent/DE60322264D1/de not_active Expired - Lifetime
  • 2003-12-03 DK DK03812825T patent/DK1581194T3/da active
  • 2003-12-03 SI SI200331302T patent/SI1581194T1/sl unknown
  • 2003-12-03 JP JP2004559355A patent/JP2006511520A/ja active Pending
  • 2003-12-08 TW TW092134590A patent/TWI361700B/zh active
  • 2003-12-10 MY MYPI20034728A patent/MY140947A/en unknown
• 2005
  • 2005-06-07 NO NO20052734A patent/NO338696B1/no not_active IP Right Cessation
  • 2005-06-10 IS IS7889A patent/IS2877B/is unknown
• 2008
  • 2008-10-14 CY CY20081101137T patent/CY1108414T1/el unknown

Also Published As

Similar Documents

Legal Events